Determining the optimal sequencing of anti-BCMA therapies in multiple myeloma
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses the ongoing debate around the optimal sequencing of anti-BCMA therapies for the treatment of multiple myeloma. Prof. Mohty first highlights the benefits and drawbacks of CAR-T therapy and bispecific antibodies, and further comments on how prior treatment with bispecifics may impact patient response to subsequent treatment with CAR-T cells. Several factors, including practicality, appear to play a role in determining the optimal sequencing of these agents. This interview took place at the EBMT-EHA 5th European CAR T-cell Meeting held in Rotterdam, The Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found